北京若生智能科技有限公司
Drug Database
T1

T1/C20 (T1/C20)

✓ Approved

Canndoc · 治疗药物

什么是 T1/C20？

T1/C20 是一种治疗药物，由Canndoc研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名T1/C20
公司Canndoc
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Canndoc

治疗适应症

T1/C20 针对 7 个适应症，涉及 4 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Nervous system disordersEpilepsy✓ Approved
Nervous system disordersMultiple sclerosis✓ Approved
Psychiatric disordersPost-traumatic stress disorder✓ Approved

注册免费账户还可查看另外 2 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedGlobal spine journal2026-10-26

Long-Term Outcomes of the Sliding-Growing Rod Technique in Early-Onset Scoliosis: Deformity Control, Spinal Growth, and Implant Survival.

Karataş Muhammed Enes ME, Karaca Salih S, Turğut Hasan H, Tatar Öner Ö et al.

Study DesignRetrospective study.ObjectivesTo evaluate the long-term outcomes of sliding-growing rod technique (SGRT) in early-onset scoliosis and assess rod translation through the domino connector as a radiographic marker of preserved sliding function during postoperative spinal growth.MethodsConsecutive patients who underwent primary SGRT between 2012 and 2019 were reviewed. Inclusion required at least 5 years of follow-up and complete radiographic and revision data. Major Cobb angle, T1-S1 and T1-T12 lengths, and rod translation were measured serially. Correction-related length gain was analyzed separately from subsequent postoperative growth. Correlation analyses assessed the relationship between rod translation and T1-S1 growth, and revision-free implant survival was estimated using Kaplan-Meier analysis.ResultsTwenty-three patients were followed for a mean of 93.9 ± 16.8 months. The major Cobb angle improved from 78.9 ± 12.3° preoperatively to 19.3 ± 7.0° early postoperatively and was 24.6 ± 7.4° at final follow-up. Postoperative longitudinal length gain was 106.0 mm for T1-S1 and 72.9 mm for T1-T12, with annualized postoperative radiographic length-gain rates of 13.9 and 9.6 mm/year, respectively. Final rod translation was 56.4 ± 7.8 mm and correlated with postoperative T1-S1 growth (r = 0.73, P < .001). Four patients underwent unplanned revision. Revision-free implant survival was 95.7% at 2 years, 91.3% at 5 years, and 82.6% at 6 years. The mean final EOSQ-24 score was 79.9 ± 11.3.ConclusionsSGRT treatment was associated with durable correction, continued postoperative spinal length gain, and acceptable revision-free implant survival without planned lengthening procedures. Serial rod translation may provide a reproducible radiographic marker of preserved sliding function during follow-up.

PMID 42929062
阅读全文 →
PubMedDentistry journal2026-10-26

Design Modifications of the Twin-Block Appliance: Facial and Dentoalveolar Outcomes in Class II Individuals.

Maximino Milia Omar O, Martín Moreno Mercedes M, De la Cruz Vigo Susana S, López-Jiménez Alberto-José AJ

Objective: This study aimed to evaluate and compare the sagittal and vertical cephalometric changes observed in growing patients with Class II malocclusion and permanent dentition treated with a Modified Twin Block (TBM) with those observed in a historical control group of untreated individuals. Materials and Methods: An observational, comparative, longitudinal, retrospective study was conducted using 240 lateral cephalometric radiographs from 120 individuals with Class II malocclusion and mandibular retrusion relative to the maxilla. The treatment group (TG) comprised 60 patients previously treated with the Modified Twin Block (TBM), aged 11.5-14 years at the initial assessment (T1), whereas the control group (CG) comprised 60 untreated individuals retrospectively selected from historical records in the AAOF Craniofacial Growth Legacy Collection. Two cephalometric records were analysed for each individual (T1 and T2). Eleven cephalometric variables representing the sagittal, vertical, and angular dimensions included in Areas 1, 2, and 5 of the cephalometric protocol were evaluated. Changes were calculated as T2 - T1 and compared between groups for the overall sample and after stratification by sex. The p values for the 33 comparisons were adjusted using the Benjamini-Hochberg procedure to control the false discovery rate. Between-group mean differences, 95% confidence intervals, and effect sizes using Hedges' g were also calculated. As a sensitivity analysis, linear regression models were fitted adjusting for the corresponding baseline cephalometric value, age at T1, sex, and the duration of the T1-T2 interval, with HC3 robust standard errors. Results: No statistically significant age differences were observed between groups at T1 or T2. However, the T1-T2 observation interval was significantly longer in the control group than in the treatment group (1.80 ± 0.31 vs. 1.65 ± 0.26 years; p = 0.004). After Benjamini-Hochberg correction of the 33 comparisons, statistically significant between-group differences remained for seven variables in the overall sample. In the multivariable sensitivity analysis, after adjustment for the baseline cephalometric value, age at T1, sex, and observation-interval duration, followed by correction for multiple comparisons, differences remained significant for A-N, S-Go, A-Me, N-Me, and ANB. Adjusted TG - CG differences were -1.70 for A-N (95% CI: -2.36 to -1.04), +2.29 for S-Go (95% CI: 1.04 to 3.53), +1.50 for A-Me (95% CI: 0.53 to 2.47), +3.49 for N-Me (95% CI: 2.01 to 4.96), and -1.04° for ANB (95% CI: -1.46 to -0.62). No significant differences were observed in functional occlusal plane inclination. Interaction analyses provided no statistically significant evidence of differences between males and females in treatment-group-associated changes. Conclusions: In growing patients with Class II malocclusion and permanent dentition, TBM treatment was associated with differences in sagittal and vertical cephalometric changes compared with the historical control group. The most consistent findings involved A-N, S-Go, A-Me, N-Me, and ANB and remained significant after multivariable adjustment and correction for multiple comparisons. These results should be interpreted in light of the retrospective, non-randomised design, the use of historical controls, the absence of a homogeneous indicator of skeletal maturation, and the lack of long-term follow-up.

PMID 42930414
阅读全文 →
PubMedHeadache2026-10-26

Impact of sphenopalatine ganglion blocks on high-frequency episodic and chronic migraine: A retrospective study.

Vinciguerra Luisa L, Brusaferri Fabio F, Zito Antonio A, Saponara Riccardo R et al.

The aim of this study was to assess the effectiveness and safety of sphenopalatine ganglion block using a dedicated catheter device in a migraine population. Sphenopalatine ganglion block has been used by clinicians in the treatment of headache disorder. The sensory and autonomic fibers that travel through the sphenopalatine ganglion provided the rationale for symptoms associated with these syndromes. Among different devices, dedicated transnasal catheter devices enable targeted delivery of local anesthetics (e.g., lidocaine) to the sphenopalatine ganglion region. To date, there are no randomized controlled trials evaluating transnasal sphenopalatine ganglion block performed with a dedicated catheter device in treatment and prevention of migraine. We conducted an open label, uncontrolled, retrospective, single-center study to evaluate the characteristics and outcomes of patients affected by high-frequency episodic or chronic migraine with or without medication overuse, according to the criteria of the International Classification of Headache Disorders, 3rd edition. We assessed changes in the Migraine Disability Assessment Questionnaire, Numeric Pain Rating Scale, Monthly Migraine Days (MMDs), and Monthly Acute Migraine Medications (MAMMs). The questionnaires were administered at baseline and 1, 3, 6, and 13 months after treatment. Patients were treated from May 2022 to December 2023. A total of 76 participants were screened, and 30 were included. After 1 and 3 months of treatment, statistically significant reductions in MMDs (median baseline [T0] vs. 1 month [T1]: 19.5 vs. 11.5, p<0.001; median T0 vs. 3 months [T2]: 19.5 vs. 16.5, p=0.009), and MAMMs (median T0 vs. T1: 20 vs. 10, p<0.001; median T0 vs. T2: 20 vs. 16; p=0.007) were detected. Numeric Pain Rating Scale (median T0 vs. T1: 8 vs. 5.5, p=0.001) and Migraine Disability Assessment Questionnaire (mean T0 vs. T2: 161.9 vs. 121.9, p<0.001) significantly decreased at T1 and T2, respectively. A marked reduction in monthly triptan and nonsteroidal anti-inflammatory drug use was observed at T1 (median T0 vs T1: 7 vs. 3.5, p<0.001 and median T0 vs T1: 16 vs. 5, p<0.001, respectively) and T2 (median T0 vs. T2: 7 vs. 4, p<0.001 and median T0 vs. T2: 16 vs. 10.5, p=0.014, respectively). Half of the patients (15/30) reached a 50% reduction in MAMMs, and 40% (12/30) of participants reported 50% reduction in MMDs at 1-month follow-up. Seventeen nonsevere adverse events were observed, mostly local discomfort. Transnasal sphenopalatine ganglion block performed with a dedicated catheter device may represent a safe therapeutic option for patients with disabling migraine. Although the procedure was associated with improvements in migraine symptoms, these findings are preliminary. Prospective studies are needed to further confirm these findings.

PMID 42928999
阅读全文 →
PubMedEpidemiologia (Basel, Switzerland)2026-10-26

Hematological Parameters and Occupational Ionizing Radiation Exposure in Interventional Healthcare Workers: A Longitudinal Matched Case-Control Study.

d'Ettorre Gabriele G, Loiacono Giuseppe G, Giannelli Gianmarco G, Piscitelli Prisco P et al.

The rising volume of fluoroscopy-guided interventions poses an occupational safety challenge for healthcare workers (HCWs) exposed to chronic low-dose ionizing radiation (LDR), which carries stochastic risks of bone marrow suppression and radiation-induced cytopenias. Real-world longitudinal evidence validating the efficacy of modern protection standards on specific peripheral hematological parameters remains limited. This study aims to evaluate the peripheral hemogram profiles of interventional HCWs exposed to LDR, compared to those of a non-exposed control cohort, from baseline (T0) to follow-up (T1). A longitudinal matched case-control study evaluated the complete blood count with differential leukograms of 136 interventional HCWs exposed to LDR compared to those of 272 matched non-exposed controls from baseline (T0) to follow-up (T1), stratifying by role, seniority, and cumulative ionizing radiation dose. The mean annual radiation dose was 0.22 mSv, and the mean cumulative radiation dose was 4.11 mSv. Hemogram indicators showed no significant differences between cases and controls at T0 and T1 (p > 0.05). Stratification by length of service (<10 vs. >10 years), and radiation dose (<3 vs. ≥3 mSv) demonstrated no significant variations in erythrocyte, leukocyte, or platelet counts. Regression analysis confirmed no association between hematological parameters and job seniority or radiation dose. All radiation doses remained below mandatory limits. The findings provide objective evidence of the effectiveness of current safety measures countering radiation-induced hematotoxicity in hospital settings. Longitudinal tracking confirms the absence of adverse hematological shifts, suggesting that structured training and strict personal protective equipment (PPE) use mitigate hematotoxicity risks among interventional staff exposed to ionizing radiation in healthcare settings. Safety protocols should maintain strict PPE compliance and safety training. Occupational health policy needs to prioritize continuous dosimetry monitoring, as routine hematological screening may not show early low-dose exposure effects.

PMID 42930335
阅读全文 →
PubMedOmics : a journal of integrative biology2026-10-26

Patient-Level Glioblastoma Recurrence Trajectories and a Candidate EGFR/NFIA-Associated Expression Module.

Alexopoulos Georgios G, Karampelas Ioannis I

Matched single-cell analyses may reveal glioblastoma recurrence changes obscured by pooled comparisons. We reanalyzed tumor-classified cells from 9 Wang primary-recurrent pairs and 59 paired CARE patients using recurrent-minus-primary program vectors. Five of nine Wang pairs were assigned an astrocytic-like (AC-like) route, but its exact 95% proportion interval was 21-86%, and an exact paired sign-flip test did not establish an excess of this route (p = 0.227). Continuous positive-program contributions indicated mixed trajectories. A 10-gene candidate expression module selected from 5 Wang AC-like pairs increased in all 11 CARE AC-like patients in the original sample-level analysis (median T2-T1 score +0.277), versus 13 of 48 other patients (median -0.125). In the CARE authors' copy-number-informed malignant-cell table, 242,702 cells from paired T1/T2 samples were scored; the mean paired score change was +0.412 in AC-like patients and -0.158 in others (between-group difference +0.570, 95% confidence interval 0.321-0.820). Enrichment implicated glutamate transport but does not establish a single pathway or EGFR/NFIA causality. These findings support a recurrence-associated candidate module in an independent cohort while leaving discovery-route frequency, mechanistic function, and spatial localization unresolved.

PMID 42928478
阅读全文 →
PubMedAnalytical methods : advancing methods and applications2026-10-26

Development of a validated ultra-fast UPLC-MS/MS method for famciclovir quantification in human liver microsomes: NADPH-independent metabolic stability.

Attwa Mohamed W MW, AlRabiah Haitham H, Kadi Adnan A AA

An ultra-fast UPLC-MS/MS method was developed and validated for measuring famciclovir (Famvir®; FMV), the orally bioavailable prodrug of the antiherpetic nucleoside analog penciclovir, in human liver microsomes (HLMs). Chromatographic separation was conducted utilizing a Luna 3 µm HILIC column (200 Å: 50 × 2 mm), with the mobile phase comprising 0.1% formic acid in ACN (90%) and 10 mM ammonium formate in water (10% at pH 3.2 by adding a few drops of HCOOH), and the total run time was 1.0 min at a 0.4 mL min-1 flow rate. The method was linear over the range of 1 to 4000 ng mL-1 (R2 = 0.9932; y = 1.2854x + 0.41327, 1/x weighting), with an LLOQ of 1 ng mL-1. Intra-day accuracy ranged from -2.84% to 8.67%, with precision (RSD) of 1.11-5.07%; inter-day accuracy ranged from -3.34% to 11.0%, with precision of 0.59-4.50%. Extraction recovery was 102.92 ± 4.16% (FMV) and 101.96% ± 5.99% (fedratinib). Three independent greenness metrics indicated the method's greenness: AGREEprep 0.64/1.00, ComplexMoGAPI 65.0/100, and AGSA 62.50/100. Applying this validated method to substrate depletion in HLMs + NADPH yielded an in vitro t1/2 of 15.72 min and a Clint of 51.56 mL min-1 kg-1, and in HLMs -NADPH (t1/2: 18.18 min and Clint: 44.59 mL min-1 kg-1), confirming its usefulness for high-clearance DMPK studies. FMV depletion in HLM is esterase-driven and NADPH-independent (as it has a minor effect on FMV metabolic stability). To our knowledge, this is the first validated, sustainability-assessed UPLC-MS/MS method for FMV in HLMs.

PMID 42929286
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多T1/C20